Clinical Trial Update: Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 trial update reports on receptor occupancy of ITI-007 (lumateperone) using PET in stable schizophrenia; the study has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Lumateperone (ITI-007) (lumateperone)

Snippet

Sponsor: Intra-Cellular Therapies, Inc. | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED